Tech Transfer eNews Blog

U of Bath licenses non-addictive compound for chronic pain to Phoenix PharmaLabs

By Jesse Schwartz
Published: January 13th, 2021

Preclinical drug company Phoenix PharmaLabs has entered into a license agreement with the University of Bath in England to advance a non-addictive treatment for chronic pain.

The license is centered around a compound formerly known as BU100038, which has properties similar to Phoenix’s lead compound PPL-103. Now known as PPL-138, the licensed compound will be developed to treat chronic pain without the addictive properties associated with opioids.

In addition, PPL-138 has demonstrated robust potency, long durations of action and no respiratory depression.

“We believe that this compound has the potential to be as important as PPL-103 in our pursuit to provide the next generation of non-addictive pain pharmaceuticals,” says Bill Crossman, president and CEO of Phoenix.

“Millions of people suffer from acute and chronic pain and many of them continue to suffer through their pain because of their fear of opioid addiction,” Crossman adds. “With both PPL-103 and the addition of PPL-138 to our portfolio, we believe we can help meet the unmet need for effective non-addictive treatment of moderate to severe pain.”

Source: Business Wire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment